Analyst Price Targets — IRON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 16, 2026 10:28 am | Derek Archila | Wells Fargo | $86.00 | $67.30 | TheFly | Disc Medicine price target raised to $86 from $79 at Wells Fargo |
| September 10, 2026 10:50 am | Douglas Tsao | H.C. Wainwright | $120.00 | $76.51 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON) |
| September 10, 2026 6:58 am | Roger Song | Jefferies | $128.00 | $76.51 | StreetInsider | Jefferies Reiterates Buy Rating on Disc Medicine (IRON) |
| August 17, 2026 1:03 pm | — | Morgan Stanley | $90.00 | $78.87 | TheFly | Disc Medicine price target raised to $90 from $85 at Morgan Stanley |
| June 15, 2026 8:02 pm | — | Morgan Stanley | $85.00 | $70.09 | TheFly | Disc Medicine price target raised to $85 from $80 at Morgan Stanley |
| May 14, 2026 12:09 pm | — | Morgan Stanley | $80.00 | $69.30 | TheFly | Disc Medicine price target raised to $80 from $75 at Morgan Stanley |
| February 17, 2026 1:34 pm | — | Wedbush | $88.00 | $60.28 | TheFly | Disc Medicine price target lowered to $88 from $110 at Wedbush |
| February 17, 2026 1:21 pm | Kristen Kluska | Cantor Fitzgerald | $125.00 | $60.24 | TheFly | Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald |
| February 17, 2026 1:14 pm | — | Morgan Stanley | $75.00 | $60.39 | TheFly | Disc Medicine price target lowered to $75 from $120 at Morgan Stanley |
| February 17, 2026 1:05 pm | — | Stifel Nicolaus | $110.00 | $61.43 | TheFly | Disc Medicine price target lowered to $110 from $125 at Stifel |
Latest News for IRON
NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
Disc Medicine, Inc. (IRON) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
NEW YORK, Sept. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
NEW YORK, Sept. 11, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Disc Medicine, Inc. (NASDAQ: IRON) resulting from allegations that Disc Medicine may have issued materially misleading business information to the investing public.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRON.
U.S. House Trading
No House trades found for IRON.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.